首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Combination Therapy with Indolylquinoline Derivative and Sodium Antimony Gluconate Cures Established Visceral Leishmaniasis in Hamsters
【2h】

Combination Therapy with Indolylquinoline Derivative and Sodium Antimony Gluconate Cures Established Visceral Leishmaniasis in Hamsters

机译:吲哚基喹啉衍生物与葡萄糖酸钠锑酸钠的联合治疗在仓鼠中建立内脏利什曼病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

2-(2″-Dichloroacetamidobenzyl)-3-(3′-indolylquinoline), designated indolylquinoline derivative A, reduced the splenic and the liver parasite burdens by >93.0% in Leishmania donovani-infected hamsters, whereas sodium antimony gluconate (SAG) reduced the burdens approximately 80.0%. Complete clearance of parasitemia from the livers and spleens was noticed when infected animals received indolylquinoline derivative A plus SAG, suggesting that indolylquinoline derivative A has potential as a new agent for sole or conjunctive therapy for leishmaniasis.
机译:2-(2″-二氯乙酰胺基苄基)-3-(3'-吲哚基喹啉),被指定为吲哚基喹啉衍生物A,可使感染利什曼原虫的仓鼠脾脏和肝脏中的寄生虫负担降低> 93.0%,而葡萄糖酸锑钠(SAG)减少负担约为80.0%。当感染的动物接受吲哚基喹啉衍生物A加SAG时,可以从肝脏和脾脏中完全清除寄生虫病,这表明吲哚基喹啉衍生物A有潜力作为单独或联合治疗利什曼病的新药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号